The protein plays a key role in milk production.
If breast cancer occurs, the vaccine triggers the immune system to attack the tumor and stop it from getting any bigger.
Mail Online gathered that Ms Davis was part of phase 1 of the study, which involved patients who completed treatment for earlystage triplenegative breast cancer in the past three years.
These people must be tumorfree but at high risk of recurrence to be included.
She has been given three doses of the vaccine, each two weeks apart.
She was chosen for the trial as there was a high chance the cancer would return, Mail Online reports.
Davis is awaiting the results of the trial but said the vaccine had brought her peace of mind that the disease could be behind her for good.
It all fell into place and worked out perfectly, she told Fox News though her journey is not over yet.
Im very, very excited, she said. What Im waiting to find out, what everybody is looking to see, is whether I built up an immune response to the breast cancer.
Ms Davis, a nurse from Lisbon, Ohio, around 60 miles NorthWest of Pittsburgh, found a lump in her breast in February 2018.
Her first biopsy a test done on tissue removed from a living person to check for a disease at a local hospital found no evidence of cancer.
But the lump grew over the next few months and Davis had another biopsy after an ultrasound showed abnormalities.
A week later, she was diagnosed with triplenegative breast cancer and underwent several rounds of chemotherapy and radiation, plus a double masectomy the removal of both breasts.
Triplenegative breast cancer makes up about 1015 per cent of all breast cancers.
It is called triple negative because the cancer cells do not have estrogen or progesterone receptors and also do not make any or much of the protein named HER2.
Roughly 40 percent of people with stage one to three triplenegative breast cancer will have the disease recur after treatment.
Related News All hormonal contraceptives raise breast cancer risks Study Lifestyle changes may cause surge in breast cancer Oncologists Using advanced technology in breast cancer treatment
About 91 percent of all women with the disease are still alive five years postdiagnosis.
The firstever recipient of a new breast cancer vaccine has been revealed to the public.
Jennifer Davis, of Ohio, received the breakthrough vaccine, developed by Cleveland Clinic, in October 2021.
She had previously battled triplenegative breast cancer, and went into remission in 2018.
This post was created with our nice and easy submission form. Create your post!